A transgenic mouse model for inducible and reversible dysmyelination.
Oligodendrocytes are glial cells devoted to the production of myelin sheaths. Myelination of the CNS occurs essentially after birth. To delineate both the times of oligodendrocyte proliferation and myelination, as well as to study the consequence of dysmyelination in vivo, a model of inducible dysmyelination was developed. To achieve oligodendrocyte ablation, transgenic animals were generated that express the herpes virus 1 thymidine kinase (HSV1-TK) gene under the control of the myelin basic protein (MBP) gene promoter. The expression of the MBP-TK transgene in oligodendrocytes is not toxic on its own; however, toxicity can be selectively induced by the systemic injection of animals with nucleoside analogs, such as FIAU [1-(2-deoxy-2-fluoro-beta-delta-arabinofuranosyl)-5-iodouracil]. This system allows us to control the precise duration of the toxic insult and the degree of ablation of oligodendrocytes in vivo. We show that chronic treatment of MBP-TK mice with FIAU during the first 3 postnatal weeks triggers almost a total depletion of oligodendrocytes in the CNS. These effects are accompanied by a behavioral phenotype characterized by tremors, seizures, retarded growth, and premature animal death. We identify the period of highest oligodendrocytes division in the first 9 postnatal days. Delaying the beginning of FIAU treatments results in different degrees of dysmyelination. Dysmyelination in MBP-TK mice is always accompanied by astrocytosis. Thus, this transgenic line provides a model to study the events occurring during dysmyelination of various intensities. It also represents an invaluable tool to investigate remyelination in vivo.
Mathis
C
C
Institut de Génétique et de Biologie Moléculaire et Cellulaire, National de la Recherche Scientifique/Université Louis Pasteur, 67404 Illkirch Cedex, France.
Hindelang
C
C
LeMeur
M
M
Borrelli
E
E
D000818:Animals; D000943:Antigens, Differentiation / Q000096:biosynthesis; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives*; D015152:Blotting, Northern; D001921:Brain / Q000378:metabolism / Q000473:pathology; D003711:Demyelinating Diseases / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis; D005911:Gliosis / Q000473:pathology; D018259:Herpesvirus 1, Human / Q000235:genetics; D017403:In Situ Hybridization; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D004676:Myelin Basic Protein / Q000235:genetics; D009186:Myelin Sheath / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D009836:Oligodendroglia / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009900:Optic Nerve / Q000473:pathology / Q000648:ultrastructure; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism*; D012584:Sciatic Nerve / Q000473:pathology / Q000648:ultrastructure; D013937:Thymidine Kinase / Q000235:genetics / Q000378:metabolism*
D000943:Antigens, Differentiation; D005904:Glial Fibrillary Acidic Protein; D004676:Myelin Basic Protein; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D001086:Arabinofuranosyluracil; C043457:fialuridine; D013937:Thymidine Kinase